2 Likes
Circulating calprotectin - the power to assess inflammation
- februar 2024
We are witnessing a growing demand and interest in circulating calprotectin, which we see as a testament to the biomarkerâs clinical value and potential to improve patient care. In response to this heightened interest, we have expanded our global footprint by establishing partnerships with new international collaborators. We are also delighted to welcome new routine users of Gentian GCALÂź Calprotectin Immunoassay, our turbidimetric plasma and serum calprotectin immunoassay, on a global scale.
Circulating calprotectin - assessment of inflammation
Calprotectin in plasma and serum serves as a sensitive and early biomarker for detecting inflammation and inflammatory responses in infections. Elevated levels of calprotectin are released into the bloodstream during inflammation, and the concentration of calprotectin corresponds to the extent of inflammation. Its application has been documented in various conditions, encompassing both infectious and non-infectious inflammatory scenarios.
The GCALÂź is the first turbidimetric assay for the quantitative measurement of calprotectin in plasma and serum intended as an aid in the detection and assessment of inflammation.
GCALÂź calprotectin in the ED and ICU â recent studies
Numerous studies have demonstrated the substantial value of plasma and serum calprotectin in the detection and evaluation of infections within the emergency department (ED) and intensive care unit (ICU).
The year 2023 was marked by publications of three notable clinical studies about calprotectin in the emergency setting, using the GCALÂź assay:
Karolinska University Hospital, Stockholm : This study demonstrates the feasibility of using calprotectin to aid in acute assessment and transfer decisions from the ED to the ICU or ward.
Charité University, Berlin : Preclinical results from this study, presented at ECCMID 2023, indicate the potential of calprotectin in severity assessment to predict infection, sepsis and mortality.
Health Economic Study: Exploring the predictive use of plasma calprotectin, which facilitates clinical decision making in cases of suspected sepsis, indicates that such determination has a dual impact - cost-saving and life-saving - on the healthcare system.
Calprotectin in immunology and rheumatology
Building on a vast amount of scientific evidence, calprotectin is increasingly recognised and extended to daily clinical use in immunology and rheumatology departments. An official recommendation to measure S100 proteins has been incorporated into the EULAR guideline for IL-1 mediated autoinflammatory diseases, indicating a significant step towards the routine use of calprotectin measurement in the expanding field of immunology. This development anticipates a steadily increase in adoption and routine use of calprotectin measurements within clinical routine protocols.
Literature overview: Clinical value of plasma and serum calprotectin
Several noteworthy scientific publications and reviews have discussed circulating calprotectin. You will find an overview of selected literature on calprotectin on our webpage in certain focus areas:
- Rheumatoid Arthritis (RA)
- Juvenile Idiopathic Arthritis (JIA)
- Stillâs disease (sJIA and AOSD)
- Bacterial infections and sepsis
- COVID-19
Highlight reviews from 2023:
S100A8/A9: An emerging player in sepsis and sepsis-induced organ injury
1 Like
Er ikke dette en helt rÄ kvartals- og Ärsrapport? Over 30 % vekst og betydelig Þkt kontantbeholdning? Er dette en ganske uoppdaget juvel, eller er det noe jeg ikke ser?
1 Like
Det er absolutt mye bra.
Men kontantbeholdningen er nĂ„ hĂžy grunnet unormalt lav arbeidskapital (ca 10 mill.). Arbeidskapitalen vil normalisere seg i 2024 og cashâen er da kanskje rundt 75 mNOK.
IfÞlge regnskapet per 31.12.23 er omlÞpsmidler NOK 141,2 mill⊠Herav er kontantbeholdningen NOK 87,6 mill. Kortsiktig gjeld er NOK 24,6 mill⊠Arbeidskapitalen er 141,2 - 24,6 som er NOK 116,6 mill. som er veldig solid.
Ok, ser hva som stÄr i transkriptet, men kan du forklare hvordan han kommer fram til det der? Arbeidskapital er vanligvis definert som omlÞpsmidler minus kortsiktig gjeld og den er mye stÞrre enn 30%. MÄ nesten hÞre pÄ den webcasten om han virkelig sier det som stÄr der.
Tror jeg skal begynne Ă„ kjĂžpe litt i denne
NT-proBNP kan virkelig sette fyr pÄ kursen. Synes og det er litt spennende med opsjonene som er i selskapet, ledelsen burde vÊre sultne pÄ Ä fÄ opp kursen!
2 Likes
Fin melding, disse legger sten pÄ sten i byggingen av en fin liten norsk bedrift som fort vekk kan fÄ veldig gode veksttall fremover.
3 Likes
Litt overraskende ettersom hun senest i gÄr holdt en engasjert presentasjon pÄ et seminar. Men for folk som pendler til Ä fra et annet land vil det nesten uunngÄelig vÊre en grense hvor lenge de stÄr i stillingen, og jeg tror hun har fÄtt gjort mye bra i sin periode selv om det ikke er synlig pÄ aksjekursen.
CFOâen er en bra mann i mine Ăžyne sĂ„ han kan nok styre selskapet greit i en periode i hvert fall.
2 Likes
Hun var hĂžyt ansett da hun fikk stillingen i Gent i sin tid, og har gjort en bra jobb i mine Ăžyne. Ingen dramatikk rundt dette, og hun blir anbefalt som ny styreleder i tillegg.
Kan allikevel ikke helt glemme denne artikkelen under Covid-Ă„rene 
Sundrehagen via Afseth?
1 Like